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KEY INSIGHTS 
1. The key risks identified are operational risks
and credit risks.
2. Adequate capital investment in operations and
efficient operational systems mitigate
operational risks.
3. Credit risks may be mitigated by improving
credit management systems and
diversification of financial risks.
Introduction 
Traditionally, large multi-national pharmaceutical 
companies perceived Africa as a small risky 
market. However, in recent years, there has been 
growing interest in serving markets in sub 
Saharan Africa. This renewed interest has 
appeared for two reasons; namely, the future 
business potential for these markets is large, and 
secondly, by so doing, it signals good corporate 
citizenship for the multi-national pharmaceutical 
companies.  
In spite of the apparent market potential, the 
limited ability of countries in sub Saharan Africa 
to pay, and the inconsistent flow of funds from 
donor agencies further intensify the perceived 
riskiness of this market. Further, lack of effective 
supply chains is considered a key reason for the 
slow materialization of demand in these markets. 
This thesis, therefore, attempts to find the 
appropriate supply chain strategy for a large 
pharmaceutical company to improve access to its 
medicines in sub Saharan Africa for each of the 
identified customer segments.  
Distribution systems in sub Saharan Africa  
The key steps in drug distribution are shown in 
Figure 1 below.  
Figure 1: Drug Distribution Process  (Ondari, 2005) 
Distribution of pharmaceuticals in Sub Saharan 
Africa is predominantly through three principal 
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systems, namely: public, faith-based or mission and 
private sectors. The public distribution system 
serves the public sector health facilities. Mission 
serves the public and mission health facilities as well 
as nongovernmental organizations providing 
humanitarian health services in the region 
 
A summary of the current distribution approaches is 
shown in Figure 2 below. 
 
 
Figure 2: Distribution Channel Options (Yadav et al, 
2009) 
The private serves all the sectors and is perceived 
as the most important distribution system now and in 
the future. It is estimated that the private sector 
serves 60% of the population and is the first point of 
call for seeking healthcare. 
Research methodology 
This was a case study of in-market pharmaceutical 
distribution channel strategies in Ghana.  In order to 
comprehensively study the pharmaceutical supply 
chain channel strategies in Ghana and to make valid 
conclusions, both secondary and primary data were 
collected. 
  
Data were analyzed using conceptual content 
analysis. This method was selected because the 
data were primarily qualitative in nature. The 
information obtained from the interviews conducted 
by phone and other secondary sources was grouped 
in themes and categories (concepts) that defined the 
distribution channel strategies, associated risks, and 
recommendations for risk mitigation. The results of 
the analysis were used to draw conclusions. 
 
Results and Discussion  
Comparison of the distribution channel options 
according to general criteria in business 
demonstrates the advantages of each channel (see 
Figure 3). Distribution channel options likely to be 
important in the future will be the most profitable, 
efficient, and provide quality service with the least 
risk. Distribution channel options of Agent/ 
Distributor> Wholesaler>Pharmacy/Health Service 
Provider and Subsidiary/Distributor>Van Sales> 
Pharmacy/Health Service Provider are likely to give 
the highest revenue, lower operational costs, and 
quality service with minimal risk.  
Operational cost remains high in channels providing 
mobile distribution services. Outsourcing of this 
service to third party logistics providers may be an 
option to reduce costs. 
 
 
 
Figure 3: Comparison of distribution channel options 
 
Key risks in pharmaceutical distribution  
Distribution 
Channel 
Key Risks 
Agent/ 
Distributor-
wholesaler-
pharmacy/ Health 
Service Provider 
 Competing Products at 
wholesale 
 Narrower range of products 
marketed 
 Poor diversification of risks 
among few buyers 
Agent/ 
Distributor-
Pharmacy/ health 
service provider 
 Low patronage 
 Lower product availability in 
market 
 Limited sales to selected 
customers 
Agent/ 
Distributor-van 
sales- pharmacy/ 
health service 
provider 
 High operational cost of 
vans 
 Security risks to products 
 Poor road infrastructure 
Agent/ 
wholesaler- Sub 
Wholesaler- 
Pharmacy/ health 
service provider 
 Poor storage conditions 
 Increased product damage 
 Less price control 
Subsidiary/ 
Distributor-
wholesale- 
pharmacy/health 
service provider 
 Global perspective, poor 
local strategy 
 Misunderstanding of market 
Subsidiary-
Distributor-Van 
 Less commitment to 
achieve targets 
Distribution 
Channel 
Key Risks 
Sales- 
pharmacy/health 
service provider 
 Low profitability 
Subsidiary/ 
Distributor-  
pharmacy/ health 
service provider 
 Ineffective penetration of 
product 
 Limited sales to large 
customer base 
 
According to the opinion of the stakeholders 
interviewed, risk mitigation should focus with equal 
emphasis on two main areas, credit risks and 
operational risks. Credit management is a challenge, 
as support from the banking and insurance sectors 
are minimal or inaccessible to distributors. Risk 
sharing with financial institutions, improvement of 
credit control management systems, and 
enforcement of laws governing credit systems can 
mitigate these risks.  
Operational risks are exacerbated by limited budgets 
for capital investments in operations, low 
qualification levels of operational staff, and low 
technical expertise in managing operations 
efficiently. An increase in financing of capital 
investments for operations is required to improve the 
quality of service delivered. Outsourcing to third 
party logistics providers can be used to diversify 
operational risks. Addressing these risks is crucial to 
improve distribution systems in Sub Saharan Africa.  
A possible channel to consider is the manufacturer 
establishing a commercial subsidiary and supplying 
through a set of distributors. The subsidiary will be 
able to improve risk management by collection of 
better information from distributors, pharmacies and 
health service providers to reduce uncertainty in 
demand. 
This model may reduce financial risk by the 
subsidiary supporting the distributor with training in 
sound credit management practices to improve cash 
flow. The distributor benefits from the subsidiary in 
technical support to improve operational procedures. 
Better distribution practices will reduce operational 
risks. The model will shrink the buildup of price 
margins thereby increasing affordability, and boost 
demand as the end user price is lowered. 
 
Conclusion 
The private sector plays a significant role in the 
distribution of medicines. This trend is likely to 
increase as it is viewed as a channel that can be 
used to increase access to essential medicines. The 
sector, however, faces significant challenges such 
as credit risks and operational risks that hinder its 
ability to expand access to medicines. 
 
Approaches to improve credit management and 
operational efficiency should be explored to equip 
and prepare the sector to undertake its increasing 
role as a major distribution channel for improving 
access to essential medicines in Sub Saharan 
Africa. 
The most suitable model for this market is the 
manufacturer establishing its in-country subsidiary 
and supplying through a set of distributors. This 
model will boost the private sector in its role as the 
most important distribution channel for improving 
access to essential medicines in Sub-Saharan 
Africa. 
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